Powered by

Red biotechnology

The latest articles, press releases and dossiers on red biotechnology in Baden-Württemberg

  • Article - 22-Aug-2017

    A research team from Freiburg is developing a method for identifying human influenza viruses of animal origin. This could potentially improve measures taken to prevent imminent pandemics. The researchers are working with genetically modified mice. Transgenic mice also play a role in the development of a ’universal’ influenza vaccine.

  • Article - 04-Jul-2017

    Graft-versus-host disease is a serious complication in leukaemia patients who have been given a blood stem cell transplant from a genetically different person. Prof. Dr. Nikolas von Bubnoff and Prof. Dr. Robert Zeiser from the Department of Haematology, Oncology and Stem Cell Transplantation at Freiburg University Medical Centre initiated a Germany-wide study to show that an active substance called ruxolitinib has a promising therapeutic effect. The researchers from the DKFZ were awarded the 2016 Richtzenhain Prize worth 10,000 euros for their achievement.

  • Article - 26-Jun-2017

    The pressure is on to develop novel vaccines based on messenger RNA and aimed at combating cancer and protecting against pandemics. Although mRNA vaccination as a cancer monotherapy has suffered a setback this year, the industry is nevertheless confident that it will succeed because of existing proof that mRNA vaccines stimulate the body's immune defence.

  • Article - 12-Jan-2017

    Based on an accredited test method, the Fraunhofer IGB has developed an in vitro phototoxicity assay to measure the phototoxic potential of substances in medications and lotions used to protect the skin against environmental influences, which can become toxic when exposed to UV light. The assay uses human skin cells that have been grown into three-dimensional tissue as a human skin model.

  • Article - 26-Oct-2016

    Gene therapy approaches are increasingly being used for treating life-threatening diseases in humans. GeneWerk GmbH, a spin-off of the DKFZ and the NCT in Heidelberg, offers customised, high-resolution molecular and bioinformatic analyses that ensure the efficacy and safety of gene therapy and immunotherapy studies.

  • Article - 10-Oct-2016

    Teva is investing heavily in its biotechnological production site in Ulm. On behalf of BIOPRO Baden-Württemberg, Walter Pytlik spoke with Dr. Hermann Allgaier, CEO of Teva Biotech, about the importance of biotechnology for the Group and about Teva in general. The company is headquartered in Israel.

  • Article - 05-Sep-2016

    Apogenix AG, a biopharmaceutical company from Heidelberg that specialises in immuno-oncology, develops protein drugs that target central signalling pathways involved in regulating the growth, migration and apoptosis of malfunctioning cells and thus offer novel treatment options for cancer and other malignant diseases.

  • Article - 22-Aug-2016

    A few years ago, Florian Kreppel developed a therapeutic approach that combined genetic vaccines with molecular address labels. It worked quite well, but the resulting product did not have the anticipated immunising properties and was put on the backburner. Now Kreppel's group of researchers is nearing completion of another project. The researchers plan to use a patented virotherapeutic platform technology for cancer treatment to establish a company called Ad-O-Lytics GmbH in 2017.

  • Article - 08-Aug-2016

    Around 3000 people suffer from achromatopsia in Germany. Achromatopsia is an inherited visual disorder characterised by the absence of full colour vision. The disease is caused by a genetic defect that makes the retina's cone photoreceptors, needed for daylight and colour vision, non-functional. There is currently no cure for achromatopsia. Scientists from Tübingen University Hospital and their colleagues from Munich and New York have now developed a gene therapy approach to treat the eye disease.

  • Article - 19-Jul-2016

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing the gene scissors required for the technology.

  • Article - 11-Jul-2016

    The oxidation state of the cells in our body is very important for us: if the normal balance of the distribution of endogenous oxidants is disturbed or if they attack cellular structures, cells are either unable or only partially able to fulfil their functions, and diseases develop. Dr. Tobias Dick and his team of researchers at the German Cancer Research Center (DKFZ) in Heidelberg have now developed a biosensor that facilitates real-time measurements of subtle oxidative changes in metabolism and has led to completely new insights into the body.

  • Article - 11-Jul-2016

    Natural killer cells kill tumour cells by injecting the protein HMGB1, which blocks the production of cellular energy by aerobic respiration. Researchers from Heidelberg have elucidated this previously unknown cancer defence mechanism and are now in the process of developing a new immunotherapy for treating cancer patients.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/biotech/